Pro-ficiency Acquires Compass

June 30, 2023

Pro-ficiency Acquires Compass Group Partners and Affiliated Assets

“The acquisition aligns with Pro-ficiency’s vision to revolutionize drug development by bridging the gap between theory and practice,” said Pro-ficiency’s CEO, Michael Raymer.

This is the second acquisition for Pro-ficiency since partnering with QHP in February of 2021. This strategic acquisition will expand simulation-based technologies into the medical affairs and commercial space, opening new avenues for innovation.

Combining Pro-ficiency’s unique simulation methodology with Compass Group Partners medical communication expertise will create revenue expansion opportunities and ultimately contribute to the delivery of safe and effective drugs to patients worldwide.

The combined company is now able to offer immersive simulation solutions to address the complexities of the medical affairs and commercial markets. Through interactive simulations, professionals in the field will gain practical experience to optimize diagnosis, treatment selection, and patient monitoring. 

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The company provides a comprehensive suite of services, anchored by their innovation in customized, virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Combined with protocol optimization, process visualization tools and professional production video capabilities, Pro-ficiency achieves improved intelligence for learners and critical risk intelligence for leaders. Learn more at pro-ficiency.com.

About Compass

Compass Group Partners was established in 2006 as a full-service marketing and communications agency in life sciences. Acquiring Eclipse Meeting Productions in 2013 and merging with Zuma Clinical Communications in 2014, the combined family of companies delivers on active partnerships with many of the top 10 global pharmaceutical companies. They are known for creating impactful, value-based and customer-centric solutions that support drug development and commercialization from development to commercialization.